Rare Cancers, Common Need

Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

Byline

Sandip Patel

S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee

Young Kwang Chae

S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee

Razelle Kurzrock

S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Judiciary News Analysis

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?

July 05, 2024

Vol.50 No.27

By Matthew Bin Han Ong

Guest Editorial Satire

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

Sometimes profoundly important public health opportunities are discovered by accident.

July 05, 2024

Vol.50 No.27

By Michael A. Friedman

Cancer History Project Guest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

July 05, 2024

Vol.50 No.27

By Katerina A. Politi and Roy S. Herbst

In the Archives

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.

July 05, 2024

Vol.50 No.27

In Brief

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Elizabeth Comen, a breast cancer oncologist and women’s health specialist known for her contributions in the field, has joined the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center as an associate professor of medicine.

July 05, 2024

Vol.50 No.27

Rare Cancers, Common Need

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Renew today!

Subscriber content

Login

Rare Cancers, Common Need

YOU MAY BE INTERESTED IN

Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care

Georgetown’s Zachary Baron on the post-Chevron era: We need guardrails about when agency expertise should be cast aside

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supplyWarning: This is not a public health recommendation. Do not implement.

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop

Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center

Login

A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.